PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 06: MARKET SEGMENTATION BY TYPE • Market segmentation by type • Comparison by type • Combination therapy - Market size and forecast 2018-2023 • Monotherapy - Market size and forecast 2018-2023 • Market opportunity by type PART 07: MARKET SEGMENTATION BY PRODUCT PART 08: CUSTOMER LANDSCAPE PART 09: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2018-2023 • Europe - Market size and forecast 2018-2023 • Asia - Market size and forecast 2018-2023 • ROW - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 10: DECISION FRAMEWORK PART 11: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 12: MARKET TRENDS • Advances in diagnostic testing for HIV • R&D of regenerative therapies • Increasing R&D of HIV vaccines PART 13: VENDOR LANDSCAPE • Overview • Landscape disruption • Competitive scenario PART 14: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • AbbVie Inc. • Boehringer Ingelheim International GmbH • Bristol-Myers Squibb Co. • F. Hoffmann-La Roche Ltd. • Gilead Sciences Inc. • GlaxoSmithKline Plc • Johnson & Johnson Services Inc. • Lupin Ltd. • Merck & Co., Inc. • Mylan NV • Pfizer Inc. • Teva Pharmaceutical Industries Ltd. PART 15: APPENDIX • Research methodology • List of abbreviations • Definition of market positioning of vendors PART 16: EXPLORE TECHNAVIO   Exhibit 01: Product overview Exhibit 02: Global pharmaceuticals market Exhibit 03: Segments of the global pharmaceuticals market Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 09: Global market: Year-over-year growth 2019-2023 (%) Exhibit 10: Five forces analysis 2018 Exhibit 11: Five forces analysis 2023 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2018 Exhibit 18: Type - Market share 2018-2023 (%) Exhibit 19: Comparison by type Exhibit 20: Combination therapy - Market size and forecast 2018-2023 ($ millions) Exhibit 21: Combination therapy - Year-over-year growth 2019-2023 (%) Exhibit 22: Monotherapy - Market size and forecast 2018-2023 ($ millions) Exhibit 23: Monotherapy - Year-over-year growth 2019-2023 (%) Exhibit 24: Market opportunity by type Exhibit 25: Market segmentation by product: overview Exhibit 26: Customer landscape Exhibit 27: Market share by geography 2018-2023 (%) Exhibit 28: Geographic comparison Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 30: North America - Year-over-year growth 2019-2023 (%) Exhibit 31: Top 3 countries in North America Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 33: Europe - Year-over-year growth 2019-2023 (%) Exhibit 34: Top 3 countries in Europe Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 36: Asia - Year-over-year growth 2019-2023 (%) Exhibit 37: Top 3 countries in Asia Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 39: ROW - Year-over-year growth 2019-2023 (%) Exhibit 40: Top 3 countries in ROW Exhibit 41: Key leading countries Exhibit 42: Market opportunity Exhibit 43: Impact of drivers and challenges Exhibit 44: Vendor landscape Exhibit 45: Landscape disruption Exhibit 46: Vendors covered Exhibit 47: Vendor classification Exhibit 48: Market positioning of vendors Exhibit 49: AbbVie Inc. - Vendor overview Exhibit 50: AbbVie Inc. - Business segments Exhibit 51: AbbVie Inc. - Organizational developments Exhibit 52: AbbVie Inc. - Geographic focus Exhibit 53: AbbVie Inc. - Key offerings Exhibit 54: AbbVie Inc. - Key customers Exhibit 55: Boehringer Ingelheim International GmbH - Vendor overview Exhibit 56: Boehringer Ingelheim International GmbH - Business segments Exhibit 57: Boehringer Ingelheim International GmbH - Organizational developments Exhibit 58: Boehringer Ingelheim International GmbH - Geographic focus Exhibit 59: Boehringer Ingelheim International GmbH - Segment focus Exhibit 60: Boehringer Ingelheim International GmbH - Key offerings Exhibit 61: Boehringer Ingelheim International GmbH - Key customers Exhibit 62: Bristol-Myers Squibb Co. - Vendor overview Exhibit 63: Bristol-Myers Squibb Co. - Business segments Exhibit 64: Bristol-Myers Squibb Co. - Organizational developments Exhibit 65: Bristol-Myers Squibb Co. - Geographic focus Exhibit 66: Bristol-Myers Squibb Co. - Key offerings Exhibit 67: Bristol-Myers Squibb Co. - Key customers Exhibit 68: F. Hoffmann-La Roche Ltd. - Vendor overview Exhibit 69: F. Hoffmann-La Roche Ltd. - Business segments Exhibit 70: F. Hoffmann-La Roche Ltd. - Organizational developments Exhibit 71: F. Hoffmann-La Roche Ltd. - Geographic focus Exhibit 72: F. Hoffmann-La Roche Ltd. - Segment focus Exhibit 73: F. Hoffmann-La Roche Ltd. - Key offerings Exhibit 74: F. Hoffmann-La Roche Ltd. - Key customers Exhibit 75: Gilead Sciences Inc. - Vendor overview Exhibit 76: Gilead Sciences Inc. - Business segments Exhibit 77: Gilead Sciences Inc. - Organizational developments Exhibit 78: Gilead Sciences Inc. - Geographic focus Exhibit 79: Gilead Sciences Inc. - Key offerings Exhibit 80: Gilead Sciences Inc. - Key customers Exhibit 81: GlaxoSmithKline Plc - Vendor overview Exhibit 82: GlaxoSmithKline Plc - Business segments Exhibit 83: GlaxoSmithKline Plc - Organizational developments Exhibit 84: GlaxoSmithKline Plc - Geographic focus Exhibit 85: GlaxoSmithKline Plc - Segment focus Exhibit 86: GlaxoSmithKline Plc - Key offerings Exhibit 87: GlaxoSmithKline Plc - Key customers Exhibit 88: Johnson & Johnson Services, Inc. - Vendor overview Exhibit 89: Johnson & Johnson Services, Inc. - Business segments Exhibit 90: Johnson & Johnson Services, Inc. - Organizational developments Exhibit 91: Johnson & Johnson Services, Inc. - Geographic focus Exhibit 92: Johnson & Johnson Services, Inc. - Segment focus Exhibit 93: Johnson & Johnson Services, Inc. - Key offerings Exhibit 94: Johnson & Johnson Services, Inc. - Key customers Exhibit 95: Lupin Ltd. - Vendor overview Exhibit 96: Lupin Ltd. - Business segments Exhibit 97: Lupin Ltd. - Organizational developments Exhibit 98: Lupin Ltd. - Geographic focus Exhibit 99: Lupin Ltd. - Key offerings Exhibit 100: Lupin Ltd. - Key customers Exhibit 101: Merck & Co. Inc. - Vendor overview Exhibit 102: Merck & Co. Inc. - Business segments Exhibit 103: Merck & Co. Inc. - Organizational developments Exhibit 104: Merck & Co. Inc. - Geographic focus Exhibit 105: Merck & Co. Inc. - Segment focus Exhibit 106: Merck & Co. Inc. - Key offerings Exhibit 107: Merck & Co. Inc. - Key customers Exhibit 108: Mylan NV - Vendor overview Exhibit 109: Mylan NV - Product segments Exhibit 110: Mylan NV - Organizational developments Exhibit 111: Mylan NV - Geographic focus Exhibit 112: Mylan NV - Segment focus Exhibit 113: Mylan NV - Key offerings Exhibit 114: Mylan NV - Key customers Exhibit 115: Pfizer Inc. - Vendor overview Exhibit 116: Pfizer Inc. - Business segments Exhibit 117: Pfizer Inc. - Organizational developments Exhibit 118: Pfizer Inc. - Geographic focus Exhibit 119: Pfizer Inc. - Segment focus Exhibit 120: Pfizer Inc. - Key offerings Exhibit 121: Pfizer Inc. - Key customers Exhibit 122: Teva Pharmaceutical Industries Ltd. - Vendor overview Exhibit 123: Teva Pharmaceutical Industries Ltd. - Business segments Exhibit 124: Teva Pharmaceutical Industries Ltd. - Organizational developments Exhibit 125: Teva Pharmaceutical Industries Ltd. - Segment focus Exhibit 126: Teva Pharmaceutical Industries Ltd. - Key offerings Exhibit 127: Teva Pharmaceutical Industries Ltd. - Key customers Exhibit 128: Validation techniques employed for market sizing Exhibit 129: Definition of market positioning of vendors

AbbVie Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson & Johnson Services Inc., Lupin Ltd., Merck & Co. Inc., Mylan NV, Pfizer Inc., and Teva Pharmaceutical Industries Ltd.